Next Article in Journal
Attitudes towards Receiving Monkeypox Vaccination: A Systematic Review and Meta-Analysis
Previous Article in Journal
The Influence of Introducing Free Vaccination against Streptococcus pneumoniae on the Uptake of Recommended Vaccination in Poland
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 12
10.3390/vaccines11121839
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Vaccines 2023, 11(1), 52.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Rockman et al. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52

by
Steven Rockman
1,2,*,
Karen Laurie
1,
Chi Ong
1,
Sankarasubramanian Rajaram
3,
Ian McGovern
4,
Vy Tran
5 and
John Youhanna
4
1
CSL Seqirus Ltd., Parkville, VIC 3050, Australia
2
Department of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3050, Australia
3
CSL Seqirus Ltd., Maidenhead SL6, UK
4
CSL Seqirus Ltd., Summit, NJ 07901, USA
5
CSL Seqirus Ltd., Kirkland, QC H9H 4M7, Canada
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(12), 1839; https://doi.org/10.3390/vaccines11121839
Submission received: 10 November 2023 / Accepted: 29 November 2023 / Published: 11 December 2023
Browse Figures
Versions Notes
The authors would like to make the following corrections to this published paper [1]. An incorrect color was assigned to season effectiveness in Figure 1d and Figure 2, due to a line color error that occurred transferring the figure from a graphics program to a word processing format. The color of the last column in Figure 1d and the color of the last column in Figure 2 (top) were both corrected. The corrected figures are shown below:
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. Rockman, S.; Laurie, K.; Ong, C.; Rajaram, S.; McGovern, I.; Tran, V.; Youhanna, J. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52. [Google Scholar] [CrossRef] [PubMed]
Vaccines 11 01839 g001
Figure 1. Seasonal influenza vaccine effectiveness in the US as estimated by the Centers for Disease Control and Prevention (CDC) [15–25]. (a) Proportions of identified virus types, subtypes, and lineages by year. (b) Adjusted vaccine effectiveness for influenza A strains. (c) Adjusted vaccine effectiveness for influenza B strains. (d) Adjusted overall seasonal effectiveness. Error bars for (b–d) indicate adjusted 95% confidence interval. ND, no data.
Figure 1. Seasonal influenza vaccine effectiveness in the US as estimated by the Centers for Disease Control and Prevention (CDC) [15–25]. (a) Proportions of identified virus types, subtypes, and lineages by year. (b) Adjusted vaccine effectiveness for influenza A strains. (c) Adjusted vaccine effectiveness for influenza B strains. (d) Adjusted overall seasonal effectiveness. Error bars for (b–d) indicate adjusted 95% confidence interval. ND, no data.
Vaccines 11 01839 g001
Vaccines 11 01839 g002
Figure 2. CDC-adjusted overall vaccine effectiveness estimates and documented A/H3N2 antigenic match or mismatch each season, as shown in Figure 1 (top), with numbers of US hospitalizations (middle) and deaths (bottom) due to influenza [15–24,26–29].
Figure 2. CDC-adjusted overall vaccine effectiveness estimates and documented A/H3N2 antigenic match or mismatch each season, as shown in Figure 1 (top), with numbers of US hospitalizations (middle) and deaths (bottom) due to influenza [15–24,26–29].
Vaccines 11 01839 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rockman, S.; Laurie, K.; Ong, C.; Rajaram, S.; McGovern, I.; Tran, V.; Youhanna, J. Correction: Rockman et al. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52. Vaccines 2023, 11, 1839. https://doi.org/10.3390/vaccines11121839

AMA Style

Rockman S, Laurie K, Ong C, Rajaram S, McGovern I, Tran V, Youhanna J. Correction: Rockman et al. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52. Vaccines. 2023; 11(12):1839. https://doi.org/10.3390/vaccines11121839

Chicago/Turabian Style

Rockman, Steven, Karen Laurie, Chi Ong, Sankarasubramanian Rajaram, Ian McGovern, Vy Tran, and John Youhanna. 2023. "Correction: Rockman et al. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52" Vaccines 11, no. 12: 1839. https://doi.org/10.3390/vaccines11121839

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop